NCT03853707View on ClinicalTrials.gov

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

January 21, 2023

Study Completion Date

September 19, 2023

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
Interventions
DRUG

Atezolizumab

Given IV

DRUG

Capecitabine

Given PO

DRUG

Carboplatin

Given IV

DRUG

Ipatasertib

Given PO

DRUG

Paclitaxel

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03853707 - Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter